A ALNY

Alnylam Pharmaceuticals Inc

BIOTECHNOLOGY · HEALTHCARE

Alnylam Pharmaceuticals, Inc. is a leading biopharmaceutical company based in Cambridge, Massachusetts, specializing in RNA interference (RNAi) therapeutics to address genetic diseases. The company has successfully launched its first commercial product and boasts a diverse pipeline of innovative RNA...

$336.19

-0.94% ($3.18)

Volume 1.38M

52W High $495.55

52W Low $205.87

Market Cap $42.58B

← Back to Calendar Compare with Others →

Next Earnings Report

Last Reported

Feb 12, 2026 Met

Actual: $1.25 vs. Consensus: $1.24

Price Chart

EPS History: Consensus vs Actual

Last 12 quarters

Price Movement Around Earnings

Q4 2025 Feb 12, 2026

1-Day: +1.92%

5-Day: +7.82%

Q3 2025 Oct 30, 2025

1-Day: +1.44%

5-Day: -5.80%

Q2 2025 Jul 31, 2025

1-Day: +2.44%

5-Day: +6.80%

Q1 2025 May 1, 2025

1-Day: +1.67%

5-Day: +5.75%

Historical Earnings

Last 12 quarters

Quarter	Date	Consensus	Whisper	Actual EPS	Surprise %	Result
Q4 2025	Feb 12, 2026	$1.24	$1.73	$1.25	+0.81%	Missed
Q3 2025	Oct 30, 2025	$1.44	$1.66	$2.90	--	Beat
Q2 2025	Jul 31, 2025	-$0.70	-$0.70	-$0.51	+27.14%	Beat
Q1 2025	May 1, 2025	-$0.37	-$0.37	-$0.01	+97.30%	Beat
Q4 2024	Feb 13, 2025	-$0.14	-$0.14	$0.06	--	Beat
Q3 2024	Oct 31, 2024	-$0.39	-$0.39	-$0.50	-28.21%	Missed
Q2 2024	Aug 1, 2024	-$1.08	-$1.08	-$0.13	+87.96%	Beat
Q1 2024	May 2, 2024	-$1.18	-$1.18	-$0.52	+55.93%	Beat
Q4 2023	Feb 15, 2024	-$1.32	-$1.32	-$1.10	+16.67%	Beat
Q3 2023	Nov 2, 2023	-$1.34	-$1.34	$1.15	--	Beat
Q2 2023	Aug 3, 2023	-$1.37	-$1.37	-$2.21	-61.31%	Missed
Q1 2023	May 4, 2023	-$1.77	-$1.77	-$1.40	+20.90%	Beat